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The outcome of hepatitis C virus (HCV) Infection 
on patient and gratt survival after orthotopic liver 
transplantation (OlT) has been controversial. An 
earlier experience with a higher dose of tacrc-
IImus (~0.1 mg/kg/d intravenously and ~0.2 mg! 
kg/d orally) was associated with a worse clinical 
outcome in patients infected with HCV. The clini-
cal outcome of 183 liver transplant recipients with 
end-stage liver disease (ESlD) secondary to HCV 
infection (HCV group) was compared with a con-
temporary cohort of 556 patients with HCV infec-
tion who underwent transplantation for nonviral, 
nonmalignant ESlD (control group). All. patients 
were prospectively screened for antl-HeV antibod-
Ies and HCV RNA by reverse-transcriptase poly-
merase chain reaction. All OlT patients were 
receiving low-dose tacrolimus immunosuppres-
sion. Cumulative patient survival rates for the 
Patients with end-stage liver disease (ESLD) 
associated with hepatitis C virus (HCY) infec-
tion account for approximately 25% of those await-
ing orthotopic liver transplantation (OLT) in the 
United States. With improvements in diagnostic 
techniques to detect HCY, it has been observed that 
recurrent HCY infection after OlT is almost univer-
sa1. l ,2 Feray et aP showed a high degree of molecu-
lar homology between pretransplantation and post-
transplantation viral isolates, confirming that the 
same strain of HCY is responsible for recurrent 
viral infection. Furthermore. Chazouilleres et al4 
have shown that the levels of serum HCY RNA 
increased significantly after OlT, and this is prob-
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HCV group were 80% after 1 year and 75% atter 3 
years compared with rates of 84% and 78%, 
respectively, in the control group (P = .452). Pri-
mary graft survival rates at the same time inter-
vals for the HeV group and the control group were 
72% and 77.S% at 1 year and 67% and 72% at 3 
years, respectively (P= .144). The incidence of 
re-transplantatlon (re-OlT) in the HCV group and 
the control group was 12.6% and 10.4%, respec-
tively (P = .42). Chronic HCV infection as an Indi-
cation for OlT with a lower dose of tacrollmus 
immunosuppression (sO.OS mg/kg/d Intrave-
nously and sO.1 mg/kg/d orally) is associated 
with a similar patient and graft survival as those 
without HeV infection. 
Copyright © 1998 by the American Association for 
the Study of Liver Diseases 
ably caused by the presence of immunosuppression 
in the postoperative period. 
The recurrence of hepatitis B virus (HBY) infec-
tion among transplant recipients has been associ-
ated with decreased patient and graft survivaP; 
these results have recently improved with long-
term prophylactic strategies,6,7 and novel antiviral 
agents may continue to improve the outcome of 
these patients. By contrast, the outcome of patients 
who have undergone OlT for ESLD associated with 
HCY infection has not been well defined. Recent 
reports have shown that long-term graft and pa-
tient survival are similar between patients with and 
without HCY infection,!I-IO although these findings 
may change when patients are followed up for 
more than 5 years after OlT. 
We have examined. in a retrospective cohort 
study, the clinical outcome of HCV infection de-
fined by the incidence of re-transplantation (re-
OLT), incidence and timing of acute cellular rejec-
tion. graft and patient survival. causes of graft 
failure, and death amon~ patients infected with 
HCY who underwent OlT for ESlD using a 
low-dose tacrolimus immunosuppressant. 
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Materials and Methods 
Between August 1991 and December 1995, 1041 adult 
patients (aged ~ 18 years) underwent pnmary OLT at the 
University of Pittsburgh Medical Center (Pittsburgh, PA) 
and received tacrolimus and sterOIds as immunosuppres-
sion treatment after transplantation. The initial dose of 
tacrolimus was 0.05 mglkgld or less intravenously and 
0.1 mglkgld or less orally. All OLT patients were prospec-
tively screened for HCY infection. 
Hev Diagnostic Testing 
Serology. Plasma samples obtained before june 1992 
were assayed for HCY antibodies using a first-generation 
(CI00-3) enzyme immunoassay (EIA) (ElA-l; Abbot 
Laboratories, Abbot Park, lL). From june 1992 to 
December 1992, specimens were processed by using 
both a second-generation EIA (C100-3, HC-31, and 
HC-34: Abbot Laboratories) and a second-generation 
recombinant immunoblot assay (RlBA \I: Chiron Corpo-
ration, Emeryville, CA), 
Reverse-transcription polymerase chain reaction. Since 
january 1993, detection of HCY RNA in plasma was 
performed by reverse-transcription polymerase chain 
reaction using liquid hybridization detection.l. ll 
Pathology. All explanted livers from patients with a 
positive serological screen for HCY were routinely exam-
ined, and a diagnosis consistent with HCY-associated 
cirrhosis was verified histopathologically, 
Patients 
Of the 1041 OlTs performed during the study period, 
183 (18%) were performed for HCY-associated ESlD. 
This group included 46 patients with a history of alcohol 
abuse confirmed by psychiatric evaluation: these patients 
fulfilled a period of 6 months of sobriety before transplan-
tation. The HCY group was compared with a contempo-
rary cohort of 556 patients (control group) who under-
went transplantation for ESlD that was not asSOciated 
with either hepatobiliary malignancy or viral causes, 
including HCY infection. 
Donor and recipient characteristics are listed in 
Table 1. The two groups were similar with respect to 
donor age and sex, cold ischemia time, and United 
Network for Organ Sharing (UNOS) status. There was a 
predominance of men and younger patients in the HCY 
group compared with the control group. 
The histopathologic diagnosis of acute rejection re-
quired the presence of a predominantly mononuclear, 
but mixed portal and/or penvenular inflammatory infil-
trate, with inflammatory infiltration and damage of a 
majority of the bile ducts and subendotheliaVperivenular 
inflammation of the portal vein branches and/or terminal 
hepatic venules. Chronic rejection was Identified by the 
presence of biliary epithelial cell atrophy/pyknOSIS in a 
majority of bile ducts, with or without varying degrees of 
Table 1. Donor and Recipient Characteristics 
HCV Control 
Group Group 
(n = 183) (n = 556) P 
Donor age (yr) 37::: 16 38::: 17 .325 
Donor sex M/F (%) 59/41 63137 .292 
Ischemia time (hr) 14 ± 4 14 ± 5 .673 
Recipient age (yr) 50 ± 9 52::: 12 .013 
Recipient sex M/F (%) 74126 56/44 .0001 
UNOS 1 +2 status (%) 73 75 .558 
Mean follow-up (rna) 41 ± 14 39::: 15 .258 
ductopenia, in a patient in whom biliary tract strictures 
have been excluded. These criteria were more stringently 
used in liver allografts with HCY infection. 
Statistical Analysis 
Continuous variables are presented as the mean :!: 
standard deviation, and categorical variables as percent-
ages. 
The standard two-sample t test was used to test 
differences between group means, whereas differences in 
proportions were tested by Pearson's chi-squared test or 
by Fisher's exact test, if expected frequenCies were less 
than 5. 
Patient survival was calculated from the time of OlT 
until death, and primary graft survival from the time of 
OlT until the first re-OlT or death with primary graft. 
Survival curves were generated using the Kaplan-Meier 
(product-limit) method12 and were compared by the 
log-rank (Mantel-Cox) test. l3 The cumulative risk for 
the first re-OlT was computed using the Kaplan-Meier 
method. Risk estimates were calculated as 1 - set) where 
set) = the cumulative probability of being re-OlT free at 
time t. The same methodology was used to compute the 
cumulative risk for acute rejection. There were 24 
patients, however. who were excluded because they 
either died or underwent re-OlT within 2 days of OlT. 
Five patients belonged to the HCY group and 19 to the 
control group: 8 patients died of primary graft failure and 
16 required re-OlT because of primary graft failure (9 
patients) and technical problems (7 patients). Cox's 
proportional hazards model l " was used to compute the 
relative risk (RR) for failure of the primary graft, RR for 
mortality for the HCY group, and 95% confidence 
intervals (CIs). Multivariate Cox regression was used to 
adjust the RR for UNOS status at the time of OlT, 
recipient sex, and year of OlT. Cox's model was also used 
to adjust the RR for donor sex, recipient and donor age. 
and cold ischemia time. For analysis of overall mortality. 
time to re-OlT was incorporated into the multivariate 
model as a lime-dependent covanant. 
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Results 
Incidence of Re-OlT and Causes 
of Graft Failure 
The overall incidence of re-OlT was similar in both 
groups. Twenty-three patients (12.5%) in the HCV 
group required re-OlT versus 58 patients 00.4%) 
in the control group (P = .422). The cumulative 
risk for re-OlT over time for both groups is shown 
in Figure 1. 
The indications for first re-OlT in the HCV and 
control groups are shown in Table 2. The most 
common indication for both groups was primary 
nonfunction (7.2%), followed by technical compli-
cations (2.4%). The incidence of acute and chronic 
rejection was similar in both study groups: 
Table 2. Indications and Incidence for First Re-OLT 
HCV Control 
Indications Group (%) Group (%) P 
PNF 16 (8.7) 38 (6.8) 
Technical 5 (2.7) 12 (2.2) 
ACR 0 1 (0.2) 
ChroniC R 2 (1.1) 5 (0.9) 
Others 0 2 (0.4) 
Total 231183 (12.S) 58/556 (10.4) .422 
AbbreViations: R. rejection: PNF. primary nonfunc· 
lion. 
Incidence and Timing of Acute Cellular 
and Chronic Rejection 
The cumulative risk for acute cellular rejection 
(ACR) over time for both groups is shown in 
Figure 2. There was no difference in the incidence 
and timing of ACR in both study groups (Table 3). 
The overall incidence of ACR was 36.6% in the 
HCV group compared with 39.6% in the control 
group. The median time to the first rejection 
episode and the incidence of multiple episodes of 
ACR were also similar in both groups (Table 3). 
The cumulative incidence of chronic rejection at 
the end of the first year was 4.6% in the control 
group and 6.3% in the HCV group. At the end of 
the fifth year, the cumulative incidence was 9.6% 
and 13.2%, respectively. These differences were not 
statistically Significant. 
The Kaplan-Meier primary graft survival for the 
HCV and control groups were 72% and 78%. 67% 
and 72%, and 57% and 65% at 1, 3, and 5 years 
afterOlT, respectively (Fig. 3; r = .144). 
Patient Survival 
The Kaplan-Meier survival rates for the HCV and 
control groups were 80% and 84%. 75% and 78%, 
and 69% and 70% at 1, 3, and 5 years after OlT, 
respectively (Fig. of; P = .452). 
Forty-siX of 183 patients in the study group also 
had a history of alcohol abuse. and they were 
diagnosed to have ESlD caused bv both HeV 
infection and alcohol. When we compared patient 
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survival rates between these two subsets of pa-
tients. Hey alone (n = 137) versus Hey plus 
alcohol (n = 46). there was no significant differ-
ence (adjusted RR = 1.13; 95% CI. 0.59 to 2.14). 
Survival rates were 81% and 76%.78% and 74%. 
and 72% and 64% at 1. 3. and 5 years after OLI 
among the groups with HCV alone and HCV plus 
alcohol. respectively (Fig. 5; P = .445). 
Table 3. Incidence and TIming of ACR 
HCV Group Control Group 
(n = 175)" (n = 540)" P 
Patients with 2: 1 
episodeACR 
(%) 64 (36.6) 214 (39.6) .471 
Cumulative risk 
10rACR at 1 
year 39.5 == 3.9 40 == 2.2 857 
Median time (d) 
to first epi-
sode (range) 13 (2·1390) 18(2·1237) 088 
Multiple episodes 
(%) 
2 9 (141) 48 (22.4) 
3 4 (6.3) 11 (5.1) 
4 1 (1.6) 2 (0.9) 
5 1 (1.6) 0 
·Patients who died or underwent re-OlT within 2 days 
post-OlT were excluded. 
Months After Transplantation 
Causes of Patient Death 
The overall mortality was similar in both groups. 
Forty-eight patients in the Hey group (26%) and 
128 patients in the control group (23%) died 
during the period of observation. Infection caused 
by bacteria and fungus were the leading causes of 
death in both groups (Table 4). Other causes of 
death included cardiac failure. multisystem organ 
failure. and post-transplant lymphoproliferative dis-
orders and were Similarly distributed in both groups. 
Multivariate Analyses 
The comparison of the HCY group with the control 
group with respect to patient and graft survival was 
adjusted for selected baseline characteristics (see 
Methods) using Cox's proportional hazards model. 
The adjusted RR for mortality for Hey patients was 
1.11 (95% Cl. 0.78 to 1.60) and the RR for primary 
graft failure was 1.28 (95% Cl. 0.93 to 1.75). 
Discussion 
OlT for ESlD caused by Hey infection was 
associated with a similar patient and graft survival 
when compared with those patients without Hey 
infection. The observed patient and graft survival 
rates among HeY-infected patients were acceptable 
despite almost universal recurrent infection: there-
fore. these patients should be conSidered for OLT 
as a therapeutic option. 
452 Casaviila et al 
-~ 
-
-= > 
'E 
= rr.J 
100 
80 
60 
\ - - -(IS) 
40 
20 --Control (n = 556) 
-- HCY(n=183) p= 0,144 (log-rank tcst) 
Figure 3, Kaplan-Meier 
primary graft survival 
from August 18, 1991, to 
December 31, 1995, The 
numbers in parentheses 
are the number of pa-
tients remaining at risk. 
6 12 18 24 30 36 42 48 54 60 66 72 
Months After Transplantation 
Our earlier experience with HeY-infected pa-
tients with a higher dose of tacrolimus (~O.l 
mglkgld intravenously and ~0.2 mglkgld orally) 
was associated with a worse clinical outcome when 
compared with a control group consisting of pa-
tients with nonviral, nonmalignant disease. 15 This 
observation raised concerns that tacrolimus-based 
immunosuppression mIght have a deleterious im-
pact on HeY-infected patients. However, under the 
current dosing of tacrolimus (SO.05 mglkgld intra-
venously and sO.1 mglkgld orally), the observed 
patient and graft survIVal were similar to those 
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achieved in the control group, as reported by other 
studies.a.lo 
It was not surprising that approXimately 25% of 
the patients with chronic Hey in this study also 
had a history of heavy alcohol intake. This associa-
tion has been established preViously and these 
patients were more likely to have a severe histo-
pathologic picture than Hey alone. 16.17 This has 
been attributed to a synergistic effect between HCV 
and alcohol. More recently, Oshita et aI's have 
reported that alcoholic patients infected with Hey 
have increased serum Hey RNA levels, and this 
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Figure 4. Kaplan-Meier 
patient survival from Au-
gust 18, 1991, to Decem-
ber 31, 1995. The num-
bers in parentheses are 
the number of patients re-
maining at risk. 
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was interpreted as reflecting an Impaired cellular 
immunity associated with alcohol intake. In our 
series, the outcome after OlT of HeY-infected 
patients with a history of alcoholism was similar to 
those with HCY infection alone, which would 
indicate that the negative effect of this combination 
may disappear after OlT. This could be caused by 
the lack of additional hepatic injury from alcohol 
in a population that is more likely to be abstinent 
after transplantation. 19 Because of the retrospective 
nature of this study, the data on alcohol recidivism 
was not complete: therefore, an analysis on the 
impact of recidivism in the natural history of HCY 
infection after liver transplantation could not be 
optimally performed. It would be worthwhile to 
investigate this issue further among patients with 
Table 4. Primary Causes of Death After OlT 
HCV Control 
Causes Group (%) Group (%) 
Bactenal sepsis 20 (42) 48 (38) 
Fungal infections 6 (12) 6 (5) 
Cardiac failure 4 (8) 14 (11) 
Multisystem failure 11 (23) 19(15) 
PTlD 1 (2) 2 (2) 
Intraoperative 1 (2) 7 (5) 
Others/unknown 5 (10) 32 (25) 
Total 48 (100) 128 (100) 
Abbreviation: PTLD. post-transplant Iymphoprolifera-
tive disorders. 
Months After Transplantation 
HCY who continue or resume alcohol use and to 
determine whether this synergistic effect continues 
to be observed after OlT. 
None of our transplant recipients infected with 
HCY presented, after OlT, an accelerated clinical 
course characterized by cholestasis and hepatic 
failure. This clinical course has been reported 
among immunosuppressed patients. It was initially 
reported in a heart transplant recipient who had 
been infected with HCV.2o Schluger et ap1 have 
recently reported this unique clinical course in 10 
of 135 patients who underwent transplantation for 
Hey disease. The failed grafts showed either cirrho-
sis or confluent hepatiC necrosis. Eight of these 
pauents required re-OlT. 
Fifty-eight patients in the HCY group received 
interferon alfa therapy at some point in their 
clinical course. None of the patients presented a 
sustained Virological or biochemical response. 
Twelve patients had a transient biochemical re-
sponse that returned to pretreatment level as soon 
as the medication was stopped. There was no 
discernible effect on the end points analyzed in this 
subset of patients. 
Bacterial sepsis and fungal infection were more 
prevalent in the Hey group as a cause of death 
after OlT, although it did not reach statistical 
significance. Singh ct alH have reported an in-
creased prevalence of serious infections in liver 
transplant reCipIents with recurrent Hev. This 
higher mcidence of mfecuon has been aunbuted to 
454 Casavdla el al 
a depressed cell-mediated ImmUnIl\' among pa-
tients infected with Hey This \,Iral InfeCtIon may 
have an immunosuppressant effect In Ilsclf. as has 
been described with c\'tomegalo\'lrus. 21 EpsteIn-
Barr virus.2; and HBV,25 although it has not been 
established so far. 
Other findings. as well as those reponed by 
other groups. showed a similar patIent and graft 
survival in a rather short obseryatlon period (:55 
years). We anticipate that. as with immunocompe-
tent pallents, Hey infectIOn ma\' slowly evolve 
toward ESlD in OlT patients. and a worse out-
come might become evident wIlh a longer fol-
low-up period. The Significant challenge that we 
face is to identify risk factors for dIsease progres-
sion and to define prophylactic and therapeutic 
strategies to prevent and treat recurrent Hey in 
this patient population. 
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